MYCN and neoplasm: Although treatment with 792 and 1154 decreased MYCN expression, we hypothesize that the lack of a larger effect on cell viability or tumor growth is likely due to the ability of cancer to proliferate via other oncogenic pathways, indicating a need for combination therapy.